Are Mangalam Drugs and Organics Ltd latest results good or bad?

The latest financial results for Mangalam Drugs and Organics Ltd reveal significant operational challenges. In Q4 FY26, the company reported net sales of ₹67.29 crores, reflecting a quarter-on-quarter growth of 15.26% from ₹58.38 crores in Q3 FY26. However, this figure represents a year-on-year decline of 7.54%, indicating ongoing demand issues. The net profit for the same quarter was a loss of ₹13.42 crores, marking a substantial deterioration compared to the previous year. The operating margin for Q4 FY26 fell to -8.35%, a stark contrast to the positive margin of 13.60% reported in Q4 FY25. This collapse in profitability is further underscored by the operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI), which resulted in a loss of ₹5.62 crores, compared to a profit of ₹9.90 crores in the same quarter last year. For the full fiscal year FY25, Mangalam Drugs recorded net sales of ₹318.00 crores, down 13.60% from ₹368.00 crores in FY24. Despite managing a profit after tax of ₹6.00 crores for FY25, the quarterly performance in FY26 has shown a troubling trend with cumulative losses of ₹44.41 crores across four quarters. The company's return on equity (ROE) has sharply declined to -15.52%, indicating a significant drop in capital efficiency. Additionally, the balance sheet reflects potential strain, with long-term debt of ₹9.23 crores against current liabilities of ₹191.60 crores, raising concerns about working capital management. Overall, the results suggest that Mangalam Drugs is facing severe operational distress, with multiple quarters of losses and a lack of institutional investor confidence. The company saw an adjustment in its evaluation, reflecting these ongoing challenges and the deterioration in financial performance.